

ORIGINAL ARTICLE

Association of rare missense variants in the second intracellular loop of Na_v1.7 sodium channels with familial autism

M Rubinstein^{1,6,7}, A Patowary^{2,7}, IB Stanaway³, E McCord¹, RR Nesbitt², M Archer², T Scheuer¹, D Nickerson³, WH Raskind^{2,4}, EM Wijsman^{3,4,5}, R Bernier², WA Catterall¹ and Z Brkanac²

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder often accompanied by intellectual disability, language impairment and medical co-morbidities. The heritability of autism is high and multiple genes have been implicated as causal. However, most of these genes have been identified in *de novo* cases. To further the understanding of familial autism, we performed whole-exome sequencing on five families in which second- and third-degree relatives were affected. By focusing on novel and protein-altering variants, we identified a small set of candidate genes. Among these, a novel private missense C1143F variant in the second intracellular loop of the voltage-gated sodium channel Na_v1.7, encoded by the *SCN9A* gene, was identified in one family. Through electrophysiological analysis, we show that Na_v1.7^{C1143F} exhibits partial loss-of-function effects, resulting in slower recovery from inactivation and decreased excitability in cultured cortical neurons. Furthermore, for the same intracellular loop of Na_v1.7, we found an excess of rare variants in a case–control variant-burden study. Functional analysis of one of these variants, M932L/V991L, also demonstrated reduced firing in cortical neurons. However, although this variant is rare in Caucasians, it is frequent in Latino population, suggesting that genetic background can alter its effects on phenotype. Although the involvement of the *SCN1A* and *SCN2A* genes encoding Na_v1.1 and Na_v1.2 channels in *de novo* ASD has previously been demonstrated, our study indicates the involvement of inherited *SCN9A* variants and partial loss-of-function of Na_v1.7 channels in the etiology of rare familial ASD.

Molecular Psychiatry (2018) **23**, 231–239; doi:10.1038/mp.2016.222; published online 13 December 2016

INTRODUCTION

Autism spectrum disorder (ASD) is a behaviorally defined, childhood-onset complex neurodevelopmental disorder with a broad spectrum of symptoms and a wide range of severity. The core symptoms of ASD include deficits in social communication and social interactions, along with restrictive, repetitive patterns of behaviors, interests or activities (DSM5).¹ A recent report by the Center for Disease Control and Prevention (CDC) puts the incidence of autism as 1 in 68 children, making it a growing public health concern. Autism has a strong genetic component that is further complicated by overlap with other neurodevelopmental disorders such as intellectual disability, epilepsy and schizophrenia.^{2,3} Advances in array and sequencing technologies facilitated elucidation of the contribution of *de novo* copy number variations and single-nucleotide mutations to the molecular basis of sporadic ASD.^{4,5} From recent copy number variations and sequencing studies, it is estimated that there are hundreds to thousands of ASD risk loci^{3,4} and *de novo* events account for 10–40% of cases.⁶ The analysis of genes with *de novo* variants using systems biology approaches such as pathway enrichment and

gene co-expression profiling implicates neuronal signaling, synaptic transmission, chromatin biology and transcription regulation^{4,5,7} in the etiology of *de novo* ASD. However, in familial ASD much of heritability remains unexplained.⁸ Traditional linkage studies have implicated regions cumulatively covering more than 10% of the genome and only a few loci have been replicated at genome-wide significance level.⁹ To identify genes involved in familial autism, new sequencing methods were initially applied in consanguineous affected individuals in order to detect recessive genes.^{10,11} More recently whole-exome sequencing has been used in multiplex families to identify heterozygous-shared variants that are associated with ASD risk.^{12,13} Such studies identified additional candidate genes for autism but lacked statistical power and did not include replication.¹⁴ Although evidence is lacking for the involvement of specific genes, some prior studies indicated an association between voltage-gated sodium channels and familial ASD.¹⁵

The alpha subunits of voltage-gated sodium (Na_v) channels are evolutionarily conserved and responsible for initiation and propagation of action potentials in nerve and muscle.¹⁶ Nine

¹Department of Pharmacology, University of Washington, Seattle, WA, USA; ²Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA; ³Department of Genome Sciences, University of Washington, Seattle, WA, USA; ⁴Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA, USA and ⁵Department of Biostatistics, University of Washington, Seattle, WA, USA. Correspondence: Professor WA Catterall, Department of Pharmacology, University of Washington, Seattle, WA 98195, USA or Dr Z Brkanac, Department of Psychiatry and Behavioral Science, University of Washington, 1959N.E. Pacific Street, Room BB1526, Seattle, WA 98195-6560, USA.

E-mail: wcatt@uw.edu or zbrkanac@uw.edu

⁶Current address: Department of Human Molecular Genetics and Biochemistry, Goldschleger Eye Research Institute, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

⁷These two authors contributed equally to this work.

Received 27 January 2016; revised 7 October 2016; accepted 17 October 2016; published online 13 December 2016

pore-forming alpha subunits of Nav channels have been identified in mammals, with different channel subtypes showing specific expression profiles in various excitable tissues. Mutations in the primary central nervous system Nav channels (encoded by *SCN1A*, *SCN2A*, *SCN3A* and *SCN8A*) are associated with neurological, psychiatric and neurodevelopmental disorders including epilepsy, autism and cognitive impairment.^{17–19} In the peripheral nervous system, Nav1.7 channels encoded by *SCN9A* are important for the excitability of sensory neurons and pain perception. Gain-of-function mutations in Nav1.7 lead to primary erythralgia,²⁰ paroxysmal extreme pain disorder,²¹ small nerve fiber neuropathy²² and increased pain perception,²³ whereas homozygous complete loss-of-function (LOF) mutations cause congenital insensitivity to pain (CIP).^{24–27} The absence of other neurological symptoms in these sensory disorders suggested that Nav1.7 channels are crucial for relaying sensory information in humans, but their roles outside the nociceptive system are not well understood.

The traditional family-based design for gene discovery uses large extended families with multiple-affected family members and combines linkage and sequencing analyses to limit the search space for variant identification and to obtain statistical evidence for causality. For study of genetically heterogeneous traits, use of extended families in this context is particularly useful.²⁸ As large multigenerational families with autism are rare, we applied a modified approach. We focused on families with affected distant relatives such as second and third cousins and used stringent frequency filtering of the exome data to identify putatively causal variants under the assumption that for each family the causal variant is private and sufficient to cause the phenotype. Our focus on protein-altering variants further narrowed the number of candidate genes in each family. This approach resulted in the identification of a small number of candidate genes in each family including *SCN9A*. Functional analysis of the *SCN9A* variant, Nav1.7^{C1143F}, revealed partial LOF effects on excitability of cultured neurons. Further case–control analysis provided additional evidence for association of Nav1.7 mutations in the second intracellular loop with ASD, and functional analysis of one of these variants, Nav1.7^{M932L/V991L}, also demonstrated reduced firing of cortical neurons. Together, our results suggest that *SCN9A* is important for normal brain function and that rare variants in this gene, encoding partial LOF mutations in the second intracellular loop of Nav1.7, are involved in familial autism.

MATERIALS AND METHODS

Study sample

For the family-based exome sequencing study we identified three second cousin and two third cousin families in the NIMH repository (<https://www.nimhgenetics.org/>) and selected two affected cousins from each family for exome sequencing ($N=10$). All families were of Caucasian background.

For the association study, we selected 855 familial Caucasian cases and 960 Caucasian controls from the NIMH repository. An additional unrelated 288 familial Caucasian cases were included from a University of Washington (UW) multiplex autism collection and 208 Caucasian subjects from a UW study on dyslexia served as control samples. For both NIMH and UW ASD subjects, the diagnostic status was determined by gold-standard ADOS and ADI-R assessment followed by expert clinical judgment using all available information. The NIMH controls sample consists of adults who completed an online short self-report assessment to exclude severe psychiatric disorders, but were not specifically screened for autism. The UW controls were assessed for dyslexia by comprehensive testing, and screened for absence of ASD with a questionnaire. Samples from NIMH participating institutions and UW were utilized in concordance with Institutional Review Boards approvals for the participation in the NIMH repository, consenting of subjects and data sharing.

Whole-exome and targeted capture sequencing, variant identification and annotation

Exome capture using the Nimblegen SeqCap EZ Human Exome Library v2.0 (Roche, Basel, Switzerland), paired-end 50 bp sequencing on an Illumina HiSeq2000 sequencing platform (San Diego, CA, USA), and variant calling and annotation were performed in the UW Genome Sciences Center for Mendelian Genomics as described before.²⁹ For targeted sequencing we designed 117 single-molecule molecular inversion probes for the protein-coding region of four candidate genes and performed sequencing and analysis as described before.³⁰ Sequence reads were aligned to NCBI human reference genome GRCh37 (hg19) using Burrows–Wheeler Aligner³¹ (BWA v0.7.10) and Genome analysis toolkit³² (GATK v2.4) was used for variant calling. Single-nucleotide variants were annotated as nonsynonymous, splice, stop gain, stop lost or synonymous using ANNOVAR³³ and further classified as rare or private based on their frequencies in variant databases. We defined variants with frequency < 0.01 in 1000 Genomes (1KG) 'European' samples as rare and variants not present in any of the data sets (dbSNP132, 1KG (April 2012) and Exome Sequencing Project (ESP) European American data sets) as private. Detailed methods are provided in the Supplementary Information.

Primary cultures of mouse cortical neurons, transient expression of Nav1.7 channels and electrophysiology

Primary cultures of cortical neurons were prepared from C57BL/6 mice on postnatal days 0–3 as described.³⁴ The cerebral cortices were dissected, digested, triturated and plated on coverslips. Cortical neurons were transfected with Nav1.7^{WT}, Nav1.7^{C1143F} and Nav1.7^{M932L/V991L} using electroporation (Neon, Life Technologies, Carlsbad, CA, USA) or Lipofectamine 2000 (Life Technologies). Co-electroporation of cDNA encoding GFP allowed identification of the transfected cells and all the recordings were performed on GFP-labeled cells only. Recordings were made 3–5 days after transfections. Detailed methods are described in the Supplementary Information.

Quantitative real-time PCR

Cerebral cortices and hippocampi were isolated from P21–P24 mice and used for quantitative real-time PCR (comparative CT method) using TaqMan primers and probes (Applied Biosystems, Foster City, CA, USA). See Supplementary Information for full description.

Genetic association analysis

For exome-sequenced cases, the level of relatedness was confirmed using KING.³⁵ We used PLINK³⁶ to identify potentially duplicated samples in case–control analysis as some UW cases were also present in the NIMH sample. Pairs with PI_HAT (Proportion IBD) more than 0.9 were considered identical/duplicates. For such pairs only one sample was considered for further analysis. For unrelated subjects we performed gene-based variant-burden and single-variant association analyses with a X^2 -test (1 df, Yates correction) and calculated a P -value for each gene/region. For the association study we included protein-altering variations (nonsynonymous, splice, stop gain and stop loss) with a frequency < 0.01 in 1KG EA. For the *SCN9A* L_{II–III} region that was associated with autism in our case–control study we performed transmission disequilibrium test (TDT) analysis to control for spurious association that might be due to population substructure. TDT uses X^2 goodness of fit statistics to determine if there is a preferential transmission of a risk allele to the affected cases. In the TDT analysis we used affected siblings of cases with rare protein-altering variants in the *SCN9A* L_{II–III} region, under the assumption that if *SCN9A* L_{II–III} variants contribute to the phenotype we should see overtransmission of risk variants to affected siblings. This analysis incorporated a rare-variant extension of the TDT as described.³⁷ In a manner equivalent to our case–control study we used a TDT-burden of rare variants that counts the number of minor-allele-transmission events to affected siblings.

Variant validation and evaluation in family members

Selected private variants identified by exome sequencing that were shared between affected cousins were independently validated using Sanger sequencing and tested for co-segregation in additional available family members. Rare variants identified in case–control-targeted sequencing that code for the second intracellular loop of *SCN9A* were also confirmed with Sanger sequencing. For each proband, available family members were

Table 1. Private variants shared by the affected cousins of each exome-sequenced family

Family id	Position	Gene	Nucleotide/ AA change	SIFT	Polyphen-2	GERP
74-0668	chr14:104029378	<i>APOPT1</i>	c.C79A:p.P27T	0.01	0	-1.81
	chr19:35850022	<i>FFAR3</i>	c.A230G:p.N77S	0.88	0.003	-6.53
152MM0304	chr1:3328298	<i>PRDM16</i>	c.G1537A:p.G513S	0.75	0.852	2.22
	chr2:167108286	<i>SCN9A</i>	c.G3428T:p.C1143F	0	1	5.82
156-3860	chr6:167594182	<i>TCP10L2</i>	c.A831T:p.E277D	1	0	-1.58
	chr8:144991583	<i>PLEC</i>	c.G12364C:p.V4122L	0.99	1	5.08
	chr11:32636075	<i>CCDC73</i>	c.G1789C:p.E597Q	0.41	0.047	1.63
156-3897	chr19:55998317	<i>NAT14</i>	c.C615G:p.D205E	0.1	0.009	0.636
	chr19:8399390	<i>KANK3</i>	c.C1321G:p.P441A	0.23	0.131	3.36
	chr19:58117083	<i>ZNF530</i>	c.A190T:p.T64S	0.79	0.001	-3.39
152MM0122	chr2:233712266	<i>GIGYF2</i>	c.G3651C:p.Q1217H	0.06	0.22	-2.51

Abbreviations: AA, amino acid; GERP, genomic evolutionary rate profiling; PolyPhen-2, polymorphism phenotyping v2; SIFT, sorting intolerant from tolerant. SIFT predicts impact of amino acid substitutions based on the degree of conservation in sequence alignments derived from closely related sequences. Scores < 0.05 are considered deleterious. PolyPhen-2 predicts impact of a variant on the structure and function of a human protein using eight sequence-based and three structure-based predictive features. Scores > 0.95 are considered probably damaging. GERP identifies functional constraint of a sequence variant by quantifying substitution deficits in multiple alignments. Substitution deficits represent a natural measure of constraint that reflects the strength of past purifying selection. Higher GERP scores are more deleterious. Genes selected for case-control study are noted in bold.

genotyped to determine if they carry the variant allele. Primers for PCR amplification and sequencing were designed using Primer3 (v 4.0.0) (<http://bioinfo.ut.ee/primer3-0.4.0/primer3/>) and bidirectional sequencing on an ABI 3730 DNA analyzer (Applied Biosystems) was done as previously described.¹³

Bioinformatics analysis of gene expression, co-expression and biological function enrichment

Expression data based on RNA sequencing of 53 different tissues, including 13 brain regions, were downloaded from the GTEx portal.³⁸ To identify genes with a brain expression pattern that correlates with that of *SCN9A*, we calculated the Pearson's correlation coefficient for each gene and *SCN9A*. Genes with strong correlation ($-0.5 \geq r \geq 0.5$) with $P < 0.05$ were retained. Pearson correlations and P -values were calculated using the *corr* function of library Hmisc in R. To identify biological implications for this set of genes we performed Gene Ontology Biological Processes enrichment analysis using Database for Annotation, Visualizations and Integration Discovery (DAVID).³⁹ For DAVID analysis Benjamini-Hochberg adjusted $P < 0.01$ and fold enrichment >2 were considered to be significant.

Genotype-phenotype correlation analysis

To investigate whether *SCN9A* L_{II-III} variants associate with a phenotypic subtype of ASD we compared available phenotypes in 29 subjects who carried L_{II-III} variants to a comparison sample of 2334 individuals from the full NIMH sample. We examined demographics, cognitive abilities (nonverbal intelligence quotient and receptive vocabulary), parental report of autism symptoms domains as assessed with the Autism Diagnostic Interview,⁴⁰ milestones (age of walking, use of first words and phrases), as well as specific clinical characteristics assessed with parental questionnaire (regression, aggression, self injury and history of seizures). To detect differences between the groups, analysis of variance was used for the quantitative variables age, cognition and parental report of autism symptom domains, whereas χ^2 nonparametric tests were used for gender and rates of specific phenotypic characteristics (for example, regression). All analyses were performed using IBM SPSS version 23.0 (Armonk, NY, USA).

RESULTS

Family exome analysis

We sequenced 10 exomes from five families with cousins affected with autism, which are deposited in NDAR (https://ndar.nih.gov/edit_collection.html?id=1919). On average, we generated 3.8 Gb of mapped sequence data per individual and > 92% of bases had > 8x coverage across all samples. After quality filtering, on average 23 685 +/- (429) variants were identified in each

individual. After frequency and function filtering was performed, each subject on average had 104 +/- (26) gene disrupting (splice, frameshift and stop) and nonsynonymous private variants (Supplementary Table 1). The affected cases in each family shared between one to four private variants that were all nonsynonymous. We evaluated the impact of missense variants on the structure and function of the proteins using physical and comparative considerations as implemented in SIFT, Polyphen2 and GERP to identify variants more likely to have effects on the protein function (Table 1). Variants were confirmed and evaluated if they were present in additional affected family members. In this way we identified four candidate genes *SCN9A*, *PLEC*, *KANK3* and *CCDC73*, which we further evaluated for association with autism. Given the strong evidence for involvement of voltage-gated sodium channels in ASD, and the high impact of the *SCN9A*^{C1143F} variant based on bioinformatics analysis, we performed functional studies on Nav1.7^{C1143F}.

Functional analysis of the Nav1.7^{C1143F} variant

To investigate the biophysical ramifications of this mutation, we first expressed Nav1.7^{WT} and Nav1.7^{C1143F} in human embryonic kidney tsA-201 cells and examined the biophysical properties of the sodium currents. When Nav1.7 channels were expressed without auxiliary β subunits, the voltage dependence and kinetics of activation and fast inactivation were unchanged by the mutation (Supplementary Figures 1a-d), but we observed a trend toward more negative voltage dependence of slow inactivation (Supplementary Figure 1e). Activation, fast inactivation and slow inactivation were unaffected by the mutation when Nav1.7 channels were co-expressed with $\beta 1$ and $\beta 2$ subunits (Supplementary Figures 1f-j).

In neurons, Nav1.7 channels have many additional interacting partners including multiple combinations of β subunits,⁴¹ fibroblast growth factor homology factors,⁴² protein kinases⁴³ and potentially other regulatory proteins. Therefore, further characterization of the Nav1.7^{C1143F} variant was carried out in cultured cortical neurons from mice. We confirmed that *SCN9A* is expressed in frontal cortex and hippocampus of mice using quantitative PCR. *SCN9A* expression is clearly detectable although 52.6 ± 5.5 -fold lower compared with the expression of *SCN1A*, a gene with a well-demonstrated role and expression in central nervous system (Supplementary Figure 2). Our results of *SCN9A* expression are in full agreement with recently published results of mouse cortex and hippocampus




Figure 1. Properties of Na_v1.7^{WT} and Na_v1.7^{C1143F} expressed in cultured cortical neurons. (a–f) Biophysical characterization of Na_v1.7^{WT} and Na_v1.7^{C1143F} in cultured cortical neurons. Because cortical neurons express endogenous Na_v1.7 channels, as well as many other types of sodium channels, we used a tetrodotoxin (TTX)-resistant form of Na_v1.7 (Supplementary Information, Na_v1.7^{Y362S}) and blocked endogenous channels with 500 nM TTX. (a) Representative set of sodium current traces from cortical neurons expressing Na_v1.7^{WT} and Na_v1.7^{C1143F}. (b) Mean current–voltage (I–V) relationships of peak currents. (c) Voltage dependence of activation (right curves, the V_{1/2} of channel activation was 19.7 ± 4.4 mV for Na_v1.7^{WT} and 19.3 ± 9.3 mV for Na_v1.7^{C1143F}, *P* > 0.05) or the voltage dependence for steady-state fast inactivation (left curves, V_{1/2} for Na_v1.7^{WT} was –62.6 ± 1.6 mV and for Na_v1.7^{C1143F} –69.7 ± 3.62 mV, *P* > 0.05). (d) Recovery from fast inactivation ($\tau = 3.72 \pm 0.6$ ms in Na_v1.7^{WT} and 7.63 ± 1.35 ms in Na_v1.7^{C1143F}, *P* = 0.017). (e and f) Mean normalized currents during 100 depolarizations to 0 mV at 20 Hz (e) and 50 Hz (f). Na_v1.7^{WT}, *n* = 7, Na_v1.7^{C1143F}, *n* = 5. (g) Representative firing in response to 160 pA depolarizing current injection. (h) Membrane input resistance. (i) Rheobase, the minimal current needed to evoke action potentials (AP) (j) average number of AP in response to 1 s depolarizing current injection at the indicated intensity. The resting membrane potential was unaffected by the C1143F mutation (–65.8 ± 2.7 mV in Na_v1.7^{WT} and –60.7 ± 3.6 mV in Na_v1.7^{C1143F}, *P* > 0.05). Similarly, the threshold for action potential (–32.7 ± 1.7 mV for Na_v1.7^{WT} and –27.68 ± 5.4 mV for Na_v1.7^{C1143F}, *P* > 0.05) and cell capacitance (95.6 ± 22 pF in Na_v1.7^{WT} and 85.3 ± 37 pF in Na_v1.7^{C1143F}, *P* > 0.05) were unchanged. **P* < 0.05. Na_v1.7^{WT}, *n* = 7, Na_v1.7^{C1143F}, *n* = 5.

single-cell RNA sequencing studies,⁴⁴ as well as with previous results from monkeys.⁴⁵ In addition evidence for *SCN9A* brain expression in mice has been documented, although not published (Mouse Genome Database (MGD), MGI: 3631994, (URL: <http://www.informatics.jax.org/>) (April 2016)).

Na_v1.7 currents recorded in voltage clamp mode with endogenous sodium channels blocked revealed that the Na_v1.7^{C1143F} mutation had no effect on peak current amplitude, voltage dependence of activation or voltage dependence of fast inactivation (Figures 1a–c). However, the rate of recovery from fast inactivation was two-fold slower in Na_v1.7^{C1143F} (Figure 1d). Sodium channel availability, during repetitive depolarization at 20 Hz and 50 Hz, declined ~20% in amplitude at both stimulation frequencies for Na_v1.7^{WT}. Notably, for Na_v1.7^{C1143F}, the decline was significantly increased, with a 35% reduction in current amplitude at 20 Hz and a 67% reduction at 50 Hz (Figures 1e and f).

The measures of cortical neuron membrane capacitance, resting membrane potential and threshold for action potential generation were comparable between neurons expressing Na_v1.7^{WT} and Na_v1.7^{C1143F} (Figure 1g). For neurons expressing Na_v1.7^{C1143F}, the input resistance was lower and rheobase increased, requiring larger current injection to evoke action potentials (Figures 1h and i; *P* < 0.05). In neurons expressing Na_v1.7^{C1143F} the number of action potentials was decreased during trains evoked by a broad range of injected current intensities (Figure 1j).

Genetic association analysis and functional analysis of the Na_v1.7^{M932L/V991L} variant

To further test the significance of mutations in *SCN9A* in autism, we conducted extensive genetic association analyses. After removal of duplicated and poorly captured samples, 1004 unrelated familial cases (NIMH cases = 800, UW cases = 204) and 1127 controls (NIMH controls = 924, UW controls = 203) remained.

Gene-based variant-burden analysis did not identify significant results for any of the four evaluated genes (Table 2). However, single-variant analysis was significant for the *SCN9A*^{V991L} rs4369876 variant ($P=0.00004$) that is located in the same cytoplasmic loop (L_{II-III}) as the C1143F variant that we observed in a single ASD exome-sequenced family. The V991L variant was previously reported to be in complete linkage disequilibrium with an M932L variant.⁴⁶ In our analysis the M932L variant was initially filtered out due to poor quality of reads for that position. Capillary sequencing confirmed the presence of M932L in all subjects with the V991L variant. Eight additional rare protein-altering variants were observed in L_{II-III} and none in controls ($P=0.0083$). For L_{II-III}, we identified a total of 29 rare variants in cases and 2 in controls for a combined variant burden L_{II-III}, $P=5.1 \times 10^{-7}$ (Table 3). Variants identified in all four genes are reported in Supplementary Table 2.

The TDT was performed on 32 affected siblings of cases that had rare gene disrupting variants in the *SCN9A* L_{II-III} region. For 25 affected siblings, the proband had the *SCN9A*^{M932L/V991L} variant, whereas for 7 siblings, the proband had the other rare L_{II-III} variants. We found overtransmission of rare alleles to affected siblings for *SCN9A*^{M932L/V991L} variant (17 minor alleles, 8 major alleles, $X^2=3.24$, $P=0.071$) and for other L_{II-III} variants (5 minor alleles, 2 major alleles, $X^2=1.28$, $P=0.256$). Combining *SCN9A*^{M932L/V991L} and other rare L_{II-III} variants the overtransmission was statistically significant (22 minor alleles, 10 major alleles, $X^2=4.5$, $P=0.033$).

As Na_v1.7^{M932L/V991L} variant, which was present in 21 cases and 2 controls, carried the bulk of genetic association, we performed

functional analysis of the Na_v1.7^{M932L/V991L} variant in cultured cortical neurons (Figure 2). Na_v1.7^{M932L/V991L} variant did not affect peak current amplitude, voltage dependence of activation, voltage dependence of fast inactivation or channel availability during repetitive depolarization at 50 Hz (Figures 2a–d). However, neurons expressing Na_v1.7^{M932L/V991L} fired fewer action potentials during 1 s long depolarizing current injection, indicating reduced excitability (Figures 2e and f).

Phenotype analysis

Available phenotypic information for the exome-sequenced families is presented in Supplementary Information. Genotype–phenotype correlation analysis for 29 subjects that had variants in *SCN9A* L_{II-III} did not reveal any specific phenotype characteristics for available measures. Phenotype information is shown in Supplementary Table 3.

Bioinformatics analysis of *SCN9A* expression, gene co-expression and biological function enrichment

In humans, the GTEx data³⁸ also confirms the expression of *SCN9A* in the brain (Supplementary Figure 3). Brain co-expression analysis of GTEx data identified 538 genes positively co-expressed with *SCN9A*. DAVID analysis identified seven enriched biological processes for *SCN9A* co-expressed genes: forebrain development and neuronal differentiation, regulation of secretion and hormone levels, cell–cell signaling, and feeding and adult behavior (Supplementary Table 4). The most significant enrichment was observed for feeding behaviors ($P=8.8 \times 10^{-6}$, 7.91-fold enrichment, 15 genes) and forebrain differentiation ($P=0.002$, 4.06-fold enrichment, 17 genes).

DISCUSSION

Although recent studies have identified multiple genetic factors involved in sporadic, *de novo* autism, genetic factors contributing to familial autism are less well characterized. Here, to identify genes that harbor rare variants that contribute to familial autism, we adopted a three-step design that combines family-based whole-exome sequencing for candidate gene identification, followed by electrophysiology studies to show functional relevance of identified variants, and additional genetic analysis to provide statistical evidence for the association with ASD. For the exome family analysis, we narrowed the number of identified genes by focusing on variants that are both private and protein disrupting. In this way we identified 11 candidate variants in 5 families. Bioinformatics analysis suggested that four of these

Table 2. Gene-based variant-burden association study for *SCN9A*, *PLEC*, *KANK3* and *CCDC73* in 1004 familial cases and 1127 unscreened controls

Gene	Case	Control	X ² -test (Yates' P-value)
<i>SCN9A</i>	67/936	60/1067	0.18
<i>SCN9A</i> (L_{II-III})	29/975	2/1119	5.1 × 10⁻⁷
<i>KANK3</i>	5/999	8/1119	0.72
<i>CCDC73</i>	1/1003	5/1122	0.27
<i>PLEC</i>	7/997	5/1122	0.62

Abbreviation: ASD, autism spectrum disorder. For *PLEC* only 1 kb coding region surrounding original variant identified in affected family was sequenced. Association for the second intracellular loop (L_{II-III}) of *SCN9A* gene is shown in bold. Case: number of ASD case samples with variant/number of ASD case samples without variant. Control: number of control samples with variant/number of control samples without variant.

Table 3. All variants identified in second intracellular loop (L_{II-III}) of *SCN9A*

Position	Nucleotide change	AA change	ESP6500 EU	1000Genome EUR	dbSNP132	Case	Control	SIFT	Polyphen-2	GERP
chr2:167099083	c.T3523A	p.Y1175N	0	0	NA	1/1003	0/1127	0	0.969	5.01
chr2:167099157	c.G3449A	p.W1150X	0	0	NA	1/1003	0/1126	0	0	1.74
chr2:167108345	c.G3369T	p.L1123F	0.000364	0.0013	NA	3/1001	0/1126	0.05	0.13	-2.18
chr2:167108386	c.C3328T	p.R1110W	0.000854	0.0026	NA	1/901	0/1091	0.01	0.6	3.92
chr2:167129091	c.G3136A	p.D1046N	0.000121	0	NA	1/1003	0/1126	1	0.003	5.42
chr2:167129135	c.C3092T	p.T1031I	0	0	NA	1/1001	0/1110	0.23	0.054	5.42
chr2:167129256	c.G2971T	p.V991L	0.004177	0	rs4369876	21/976	2/1119	0.08	0.004	-0.949
chr2:167133540 ^a	c.A2794C	p.M932L	0.004070	0	rs12478318	21/976	2/1119	0.53	0.043	5.65

Abbreviations: AA, amino acid; ASD, autism spectrum disorder; dbSNP, database of short genetic variation; ESP, Exome Sequencing Project; GERP, genomic evolutionary rate profiling; NA, variant is not present; PolyPhen-2, polymorphism phenotyping v2; SIFT, sorting intolerant from tolerant. ESP and 1000Genome frequencies are only for 'European American' and 'European' population, respectively. Case: number of ASD case samples with variant/number of ASD case samples without variant. Control: number of control samples with variant/number of control samples without variant. SIFT, Polyphen-2 and GERP are described in Table 1. ^aThis variant was initially filtered out due to poor quality of reads for that position. Capillary sequencing confirmed the presence of M932L in all subjects with the V991L variant.




Figure 2. Properties of Na_v1.7^{WT} and Na_v1.7^{M932L/V991L} expressed in cultured cortical neurons. **(a)** Representative set of sodium current traces from cortical neurons expressing Na_v1.7^{WT} and Na_v1.7^{M932L/V991L}. **(b)** Mean current–voltage (I–V) relationships of peak currents. **(c)** Voltage dependence of activation (right curves) and the voltage dependence of steady-state fast inactivation. **(d)** Mean normalized currents during 100 depolarizations to 0 mV at 50 Hz. Na_v1.7^{WT}, *n* = 4, Na_v1.7^{M932L/V991L}, *n* = 5. **(e)** and **(f)** Firing of cortical neurons expressing Na_v1.7^{WT} and Na_v1.7^{M932L/V991L}. **(e)** Representative firing in response to 100 pA depolarizing current injection. **(f)** Average number of action potentials (AP) in response to 1 s depolarizing current injection at the indicated intensity. Na_v1.7^{WT}, *n* = 7, Na_v1.7^{M932L/V991L}, *n* = 7.

variants were more likely to have functional effects. A variant-burden analysis of four genes was significant for rare protein disrupting variants in the second intracellular loop of *SCN9A*. This is the same L_{II–III} loop that harbored a *SCN9A*^{C1143F} variant in one family that was exome-sequenced. In further support of the association with autism, for L_{II–III} variants we show preferential transmission to affected siblings as well. *SCN9A* is in tight linkage disequilibrium with a cluster of sodium channel genes on chromosome 2q24.3 (*SCN1A*, *SCN2A*, *SCN3A* and *SCN7A*) and *SCN1A* is < 200 kb away. This raises the possibility that the association we have identified with *SCN9A* might be due to mutations in *SCN1A* and *SCN2A* genes that are implicated in autism as well. Although we were not able to directly sequence *SCN1A* and *SCN2A* genes, we feel that this scenario is very unlikely as the main phenotype associated with *SCN1A* (OMIM* 182389) and *SCN2A* (OMIM *182390) mutations are seizures, which are not reported in our subjects carrying *SCN9A* variants. However we cannot exclude the possibility of *SCN1A* involvement, as mutations in this gene were associated with autism without seizures as well.^{47,48} In addition to genetic association, both Na_v1.7^{C1143F} variant identified in a single exome-sequenced family and Na_v1.7^{M932L/V991L} variant identified in association analysis demonstrated a partial LOF effect when expressed in cortical neurons.

We did not find genetic evidence for association in the four other families studied by exome sequencing. This is not surprising as ASD is highly heterogeneous. In these families other genetic mechanisms, that we have not evaluated, might be contributory. Such mechanisms include disruptions of noncoding regulatory DNA,⁴⁹ genetic heterogeneity within the family⁵⁰ and polygenic inheritance.⁵¹

Functional consequences of the Na_v1.7^{C1143F} and Na_v1.7^{M932L/V991L} variants

Electrophysiological analysis of Na_v1.7^{C1143F} expressed in tsA-201 human embryonic kidney cell lines with and without auxiliary β1

and β2 subunits suggests, at most, a small effect on basic sodium channel functions. In neurons, Na_v1.7 channels have many additional interacting partners, and indeed, in cortical neurons the rate of recovery from fast inactivation was two-fold slower for Na_v1.7^{C1143F} channels. Such slowed recovery is expected to result in longer periods of reduced sodium channel availability during and following trains of stimuli. In agreement with this expectation, sodium current amplitude conducted by Na_v1.7^{C1143F} expressing neurons declined significantly more compared with Na_v1.7^{WT} during repetitive depolarization at 20 and 50 Hz. These biophysical alterations are both expected to result in reduced firing and excitability of cortical neurons. The experiments in current-clamp mode revealed that neurons expressing Na_v1.7^{C1143F} had lower input resistance and increased rheobase, so larger current injection was needed to evoke action potentials, resulting in decreased action potential firing (Figure 1).

Na_v1.7^{M932L/V991L} variant has been implicated before in neuropathic pain syndromes²² and is associated with partial deletion of pain perception,⁵² suggesting both increased and decreased neuronal firing. Here, electrophysiological analysis of Na_v1.7^{M932L/V991L} did not detect changes in the biophysical properties of the currents. However, similarly to Na_v1.7^{C1143F}, cortical neurons expressing Na_v1.7^{M932L/V991L} fired fewer action potentials, indicating reduced excitability (Figure 2). Although we do not completely understand the causes for reduced firing in the Na_v1.7^{M932L/V991L} variant, it might be related to changes in cellular localization or neuronal maturation. L_{II–III} contains binding sites for ankyrin-G that are crucial for the localization of sodium channels at the axon initial segment.⁴³ Neuronal excitability was therefore examined in mature neurons (after the formation of axon and dendrites). In contrast, biophysical characterization was performed on immature cultures (3–4 days *in vitro*) in order to avoid space clamp problems, but potentially before the manifestation of functional alterations. In addition, unlike the C1143F variant, which was found to be highly conserved and predicted to be damaging with three bioinformatics tools (Table 1), strong evidence for

conservation and potential impact on protein function is lacking for the M932L and V991L variants (Table 3). Furthermore, functional implication of M932L/V991L variant might strongly depend on genetic background, as indicated by its frequency in different populations. On the basis of ExAC database that aggregates multiple studies (www.ExAC.broadinstitute) M932L and V991L variants are rare in European (MAF=0.00236) and African American (MAF=0.0029) populations with frequencies that are comparable to our Caucasian controls (MAF=0.0016). However, M932L and V991L variants have higher frequency in East (MAF=0.061) and South Asians (MAF=0.012), and in Latino population variant frequency (MAF=0.23) far exceeds the frequency we have observed in our Caucasian cases (MAF=0.022). However, for sodium channel genes, genetic background is known to play a role in seizure phenotype expression⁵³ and in mouse model *SCN1A* mutations resulting in severe epilepsy and impaired cognitive abilities in the C57BL/6 strain and in extremely rare spontaneous seizures with normal cognitive function on the 129/SvJ background.⁵⁴

Nevertheless, although the evidence for the disease-causing role of Na_v1.7^{M932L/V991L} variant is tempered due to high population frequency of the variant in Asian and Latino populations and lack of strong evolutionary conservation, we have identified six additional rare L_{II-III} variants that support association with ASD. Overall our findings indicate that ASD-associated *SCN9A* variants result in partial LOF of Na_v1.7 channel, causing decreased action potential firing and altering the input-output relationships in circuits whose neurons express *SCN9A*.

How might Na_v1.7 channels contribute to autism?

Although traditionally considered as a gene that is important for the peripheral nervous system, there is increased understanding that *SCN9A* has a role in the central nervous system as well. Missense mutations in *SCN9A* are associated with familial febrile seizures,⁵⁵ a benign form of epilepsy. Similarly, mutations in *SCN9A* can modify the severity of Dravet syndrome, a rare genetic intractable epilepsy syndrome caused by complete LOF mutations in Na_v1.1 channels, which are prominent in interneurons of the brain.^{55,56} One emerging concept from studies of mouse models of ASDs, including idiopathic autism,⁵⁷ Rett Syndrome,⁵⁸ Fragile X Syndrome⁵⁹ and Dravet Syndrome,⁶⁰ is that core autistic-like behaviors are associated with an increased ratio of excitatory to inhibitory neurotransmission in the brain. Most of the experimental evidence suggests increased excitation. In contrast, in Dravet syndrome mice, autistic-like behaviors are caused by LOF mutations in Na_v1.1 channels and consequent selective impairment of action potential firing in GABAergic inhibitory neurons.^{60,61} These autistic-like behaviors are rescued by enhancement of inhibitory neurotransmission by treatment with low doses of clonazepam, a positive allosteric modulator of GABA_A receptors.⁶⁰ Data presented here (Supplementary Figure 2) confirm the expression of Na_v1.7 in the cortex. The single-cell neuronal gene transcription analysis by Zeisel *et al.*⁴⁴ demonstrated that the Na_v1.7 channel is expressed in both GABAergic and glutamatergic neurons, but with higher levels of expression in interneurons.⁴⁴ Thus, by analogy to LOF mutations in Na_v1.1, a hypothesis can be made that rare variants in Na_v1.7 decrease the firing of a specific set of GABAergic neurons that are important in control of social behaviors. Furthermore, using GTeX data we show that *SCN9A* is co-expressed with genes that are enriched for forebrain neuronal differentiation. These genes include transcription factors *DLX1* and *DLX2* that are essential for the production of forebrain GABAergic interneurons during embryonic development⁶² and have been implicated in autism in a genetic association study.⁶³ These observations support a hypothesis that functional variants in *SCN9A* channels contribute to autism

phenotype by affecting a specific set of GABAergic neurons that are important in control of social behaviors.

Our analyses of GTeX data indicate that *SCN9A* is highly expressed in the hypothalamus, a brain region that has been implicated in autism.^{64,65} Among other roles, the hypothalamus is responsible for synthesizing the behaviorally important hormone oxytocin that has a role in social-bonding behaviors and has been implicated in autism as well.⁶⁶ In addition, the hypothalamus is a crucial regulator of feeding behavior.⁶⁷ We have found that genes co-expressed with *SCN9A* are enriched for functions related to feeding behaviors and the function of Na_v1.7 channels in hypothalamic neurons was shown to be important for body weight regulation.⁶⁸ This indicates that, in addition to the role in GABAergic neurotransmission, the role of *SCN9A* in autism might be mediated through changes in hypothalamic functions, which in turn can affect multiple hormonally regulated processes that are frequently disrupted in autism such as oxytocin-mediated social interactions⁶⁹ and feeding behaviors.⁷⁰

Further directions

Until now, truncating mutations in Na_v1.7 with full LOF effects that completely abolish Na_v1.7 currents were found to be responsible for rare autosomal-recessive CIP.^{24–27} Fewer than 100 individuals with CIP were reported in the literature and phenotype description in these reports indicate that beyond CIP other sensory modalities are unaffected. Interestingly, extensive neuropsychological testing was reported for a single 9-year-old girl with partial CIP, caused by compound heterozygous partial LOF *SCN9A* variant. On the basis of parental report this individual had impaired social skills and below average levels of empathy.⁷¹ Although in this report presence of ASD was not evaluated, presence of deficits in social skills and empathy indicates the need for more detailed evaluation for ASD in individuals with CIP. In addition, our study has shown the association of heterozygous partial LOF variants with ASD. This indicates that carriers of *SCN9A* CIP variants might be at increased risk for autism as well, and formal ASD screening and evaluation in patients with CIP will allow to establish the diagnosis, which in turn, will improve the care and treatments such individuals are receiving.

In our sample, we were unable to detect any specific autism subtype based on demographic, ADOS variables and clinical characteristics. However, our analysis of *SCN9A* brain co-expressed genes indicates that feeding behaviors might be a prominent component of the *SCN9A*-associated phenotype. We did not have information about feeding behaviors for our cohort. Our results indicate that ASD subjects with deregulated feeding behaviors might be enriched for *SCN9A* variants. In addition dysregulated-feeding behaviors could be a phenotype that is suitable for genetic studies and it might be valuable to add such phenotype to genetic studies of autism.

The physiological role of L_{II-III} region in voltage-gated sodium channels is not well understood. Earlier human genetic studies implicates variants in L_{II-III} in a growing number of hereditary disorders including cardiac arrhythmias^{72–74} and epilepsy,⁵⁶ and we now add the association with ASD. Reported functional analysis of these variants demonstrated effects on channel inactivation,^{72–75} and we report alterations in the rate of recovery from fast inactivation and neuronal excitability (Figures 1–2). Further functional studies on *SCN9A* and other brain expressed Na_v family genes that examine electrophysiological properties and subcellular localization in specific cell subtypes like GABAergic neurons are warranted to further elucidate the mechanism by which Na_v channels L_{II-III} variants increase the risk for ASD. In addition, pharmacological interventions in *SCN1A*-null mice that reverse ASD-like symptoms⁶⁰ indicate that for individuals with ASD and Na_v mutations ASD, symptoms might be responsive to pharmacological interventions as well.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

We acknowledge the clinicians, organizations and families that contributed to data and samples used in this study (<https://www.nimhgenetics.org/acknowledgements.php>). DNA samples and phenotype information were obtained from NIMH Center for Collaborative Genomic Research on Mental Disorders. AP acknowledges Dr Fernando Gelin for his help in generating Supplementary Figure 3. MR and WAC acknowledge Dr Gilbert Martinez for assistance with molecular biology. Research reported in this publication was supported by funding from the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke under award numbers R01 MH092367, R01 NS25704 from the National Institutes of Health and research grant number 240243 from the Simons Foundation.

DISCLAIMER

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Simons Foundation.

REFERENCES

- 1 Diagnostic and statistical manual of mental disorders (5th edn). American Psychiatric Association. Washington, DC, 2013.
- 2 Tuchman R, Rapin I. Epilepsy in autism. *Lancet Neurol* 2002; **1**: 352–358.
- 3 Hoischen A, Krumm N, Eichler EE. Prioritization of neurodevelopmental disease genes by discovery of new mutations. *Nat Neurosci* 2014; **17**: 764–772.
- 4 lossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D et al. The contribution of *de novo* coding mutations to autism spectrum disorder. *Nature* 2014; **515**: 216–221.
- 5 Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. *Am J Hum Genet* 2014; **94**: 677–694.
- 6 Berg JM, Geschwind DH. Autism genetics: searching for specificity and convergence. *Genome Biol* 2012; **13**: 247.
- 7 De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE et al. Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature* 2014; **515**: 209–215.
- 8 Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. *Curr Opin Genet Dev* 2012; **22**: 229–237.
- 9 Freitag CM. The genetics of autistic disorders and its clinical relevance: a review of the literature. *Mol Psychiatry* 2007; **12**: 2–22.
- 10 Shi L, Zhang X, Golhar R, Otieno FG, He M, Hou C et al. Whole-genome sequencing in an autism multiplex family. *Mol Autism* 2013; **4**: 8.
- 11 Chahrouh MH, Yu TW, Lim ET, Ataman B, Coulter ME, Hill RS et al. Whole-exome sequencing and homozygosity analysis implicate depolarization-regulated neuronal genes in autism. *PLoS Genet* 2012; **8**: e1002635.
- 12 Toma C, Torricio B, Hervas A, Valdes-Mas R, Tristan-Noguero A, Padillo V et al. Exome sequencing in multiplex autism families suggests a major role for heterozygous truncating mutations. *Mol Psychiatry* 2014; **19**: 784–790.
- 13 Chapman NH, Nato AQ Jr., Bernier R, Ankenman K, Sohi H, Munson J et al. Whole exome sequencing in extended families with autism spectrum disorder implicates four candidate genes. *Hum Genet* 2015; **134**: 1055–1068.
- 14 Sham PC, Purcell SM. Statistical power and significance testing in large-scale genetic studies. *Nat Rev Genet* 2014; **15**: 335–346.
- 15 Weiss LA, Escayg A, Kearney JA, Trudeau M, MacDonald BT, Mori M et al. Sodium channels SCN1A, SCN2A and SCN3A in familial autism. *Mol Psychiatry* 2003; **8**: 186–194.
- 16 Catterall WA. Voltage-gated sodium channels at 60: structure, function and pathophysiology. *J Physiol* 2012; **590**: 2577–2589.
- 17 Catterall WA, Kalume F, Oakley JC. Nav1.1 channels and epilepsy. *J Physiol* 2010; **588**: 1849–1859.
- 18 Imbrici P, Camerino DC, Tricarico D. Major channels involved in neuropsychiatric disorders and therapeutic perspectives. *Front Genet* 2013; **4**: 76.
- 19 O'Brien JE, Meisler MH. Sodium channel SCN8A (Nav1.6): properties and *de novo* mutations in epileptic encephalopathy and intellectual disability. *Front Genet* 2013; **4**: 213.
- 20 Drenth JP, te Morsche RH, Guillet G, Taieb A, Kirby RL, Jansen JB. SCN9A mutations define primary erythralgia as a neuropathic disorder of voltage gated sodium channels. *J Invest Dermatol* 2005; **124**: 1333–1338.

- 21 Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. *Neuron* 2006; **52**: 767–774.
- 22 Faber CG, Hoeijmakers JG, Ahn HS, Cheng X, Han C, Choi JS et al. Gain of function Nav1.7 mutations in idiopathic small fiber neuropathy. *Ann Neurol* 2012; **71**: 26–39.
- 23 Reimann F, Cox JJ, Belfer I, Diatchenko L, Zaykin DV, McHale DP et al. Pain perception is altered by a nucleotide polymorphism in SCN9A. *Proc Natl Acad Sci USA* 2010; **107**: 5148–5153.
- 24 Kurban M, Wajid M, Shimomura Y, Christiano AM. A nonsense mutation in the SCN9A gene in congenital insensitivity to pain. *Dermatology* 2010; **221**: 179–183.
- 25 Nilsen KB, Nicholas AK, Woods CG, Mellgren SI, Nebuchennykh M, Aasly J. Two novel SCN9A mutations causing insensitivity to pain. *Pain* 2009; **143**: 155–158.
- 26 Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M et al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifferece to pain in multiple human populations. *Clin Genet* 2007; **71**: 311–319.
- 27 Ahmad S, Dahllund L, Eriksson AB, Hellgren D, Karlsson U, Lund PE et al. A stop codon mutation in SCN9A causes lack of pain sensation. *Hum Mol Genet* 2007; **16**: 2114–2121.
- 28 Wijsman EM. The role of large pedigrees in an era of high-throughput sequencing. *Hum Genet* 2012; **131**: 1555–1563.
- 29 O'Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, Girirajan S et al. Exome sequencing in sporadic autism spectrum disorders identifies severe *de novo* mutations. *Nat Genet* 2011; **43**: 585–589.
- 30 Boyle EA, O'Roak BJ, Martin BK, Kumar A, Shendure J. MIPgen: optimized modeling and design of molecular inversion probes for targeted resequencing. *Bioinformatics* 2014; **30**: 2670–2672.
- 31 Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009; **25**: 1754–1760.
- 32 McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010; **20**: 1297–1303.
- 33 Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010; **38**: e164.
- 34 Slutsky I, Sadeghpour S, Li B, Liu G. Enhancement of synaptic plasticity through chronically reduced Ca²⁺ flux during uncorrelated activity. *Neuron* 2004; **44**: 835–849.
- 35 Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship inference in genome-wide association studies. *Bioinformatics* 2010; **26**: 2867–2873.
- 36 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; **81**: 559–575.
- 37 He Z, O'Roak BJ, Smith JD, Wang G, Hooker S, Santos-Cortez RL et al. Rare-variant extensions of the transmission disequilibrium test: application to autism exome sequence data. *Am J Hum Genet* 2014; **94**: 33–46.
- 38 Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multi-tissue gene regulation in humans. *Science* 2015; **348**: 648–660.
- 39 Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009; **4**: 44–57.
- 40 Michael Rutter ALC, Catherine Lord. *ADI-R Autism Diagnostic Interview-Revised*. Western Psychological Services: Los Angeles, USA, 2003.
- 41 Ho C, Zhao J, Malinowski S, Chahine M, O'Leary ME. Differential expression of sodium channel beta subunits in dorsal root ganglion sensory neurons. *J Biol Chem* 2012; **287**: 15044–15053.
- 42 Goldfarb M, Schoorlemmer J, Williams A, Diwakar S, Wang Q, Huang X et al. Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channels. *Neuron* 2007; **55**: 449–463.
- 43 Leterrier C, Brachet A, Fache MP, Dargent B. Voltage-gated sodium channel organization in neurons: protein interactions and trafficking pathways. *Neurosci Lett* 2010; **486**: 92–100.
- 44 Zeisel A, Munoz-Manchado AB, Codeluppi S, Lonnerberg P, La Manno G, Jureus A et al. Brain structure. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. *Science* 2015; **347**: 1138–1142.
- 45 Raymond CK, Castle J, Garrett-Engle P, Armour CD, Kan Z, Tsinoremas N et al. Expression of alternatively spliced sodium channel alpha-subunit genes. Unique splicing patterns are observed in dorsal root ganglia. *J Biol Chem* 2004; **279**: 46234–46241.
- 46 Li QS, Cheng P, Favis R, Wickenden A, Romano G, Wang H. SCN9A variants may be implicated in neuropathic pain associated with diabetic peripheral neuropathy and pain severity. *Clin J Pain* 2015; **31**: 976–982.
- 47 Li J, Shi M, Ma Z, Zhao S, Euskirchen G, Ziskin J et al. Integrated systems analysis reveals a molecular network underlying autism spectrum disorders. *Mol Syst Biol* 2014; **10**: 774.

- 48 Alvarez-Mora MI, Calvo Escalona R, Puig Navarro O, Madrigal I, Quintela I, Amigo J *et al*. Comprehensive molecular testing in patients with high functioning autism spectrum disorder. *Mutat Res* 2016; **784-785**: 46–52.
- 49 Turner TN, Hormozdiari F, Duyzend MH, McClymont SA, Hook PW, Iossifov I *et al*. Genome sequencing of autism-affected families reveals disruption of putative noncoding regulatory DNA. *Am J Hum Genet* 2016; **98**: 58–74.
- 50 Yuen RK, Thiruvahindrapuram B, Merico D, Walker S, Tammimies K, Hoang N *et al*. Whole-genome sequencing of quartet families with autism spectrum disorder. *Nat Med* 2015; **21**: 185–191.
- 51 Talkowski ME, Minikel EV, Gusella JF. Autism spectrum disorder genetics: diverse genes with diverse clinical outcomes. *Harv Rev Psychiatry* 2014; **22**: 65–75.
- 52 Yuan R, Zhang X, Deng Q, Si D, Wu Y, Gao F *et al*. Two novel SCN9A gene heterozygous mutations may cause partial deletion of pain perception. *Pain Med* 2011; **12**: 1510–1514.
- 53 Ragsdale DS. How do mutant Nav1.1 sodium channels cause epilepsy? *Brain Res Rev* 2008; **58**: 149–159.
- 54 Rubinstein M, Westenbroek RE, Yu FH, Jones CJ, Scheuer T, Catterall WA. Genetic background modulates impaired excitability of inhibitory neurons in a mouse model of Dravet syndrome. *Neurobiol Dis* 2015; **73**: 106–117.
- 55 Singh NA, Pappas C, Dahle EJ, Claes LR, Pruess TH, De Jonghe P *et al*. A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. *PLoS Genet* 2009; **5**: e1000649.
- 56 Mulley JC, Hodgson B, McMahon JM, Iona X, Bellows S, Mullen SA *et al*. Role of the sodium channel SCN9A in genetic epilepsy with febrile seizures plus and Dravet syndrome. *Epilepsia* 2013; **54**: e122–e126.
- 57 Han S, Tai C, Jones CJ, Scheuer T, Catterall WA. Enhancement of inhibitory neurotransmission by GABA_A receptors having alpha2,3-subunits ameliorates behavioral deficits in a mouse model of autism. *Neuron* 2014; **81**: 1282–1289.
- 58 Dani VS, Chang Q, Maffei A, Turrigiano GG, Jaenisch R, Nelson SB. Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. *Proc Natl Acad Sci USA* 2005; **102**: 12560–12565.
- 59 D'Hulst C, Kooy RF. The GABA_A receptor: a novel target for treatment of fragile X? *Trends Neurosci* 2007; **30**: 425–431.
- 60 Han S, Tai C, Westenbroek RE, Yu FH, Cheah CS, Potter GB *et al*. Autistic-like behaviour in *Scn1a*^{+/-} mice and rescue by enhanced GABA-mediated neurotransmission. *Nature* 2012; **489**: 385–390.
- 61 Rubinstein M, Han S, Tai C, Westenbroek RE, Hunker A, Scheuer T *et al*. Dissecting the phenotypes of Dravet syndrome by gene deletion. *Brain* 2015; **138**(Pt 8): 2219–2233.
- 62 Cobos I, Calcagnotto ME, Vilaythong AJ, Thwin MT, Noebels JL, Baraban SC *et al*. Mice lacking *Dlx1* show subtype-specific loss of interneurons, reduced inhibition and epilepsy. *Nat Neurosci* 2005; **8**: 1059–1068.
- 63 Liu X, Novosedlik N, Wang A, Hudson ML, Cohen IL, Chudley AE *et al*. The *DLX1* and *DLX2* genes and susceptibility to autism spectrum disorders. *Eur J Hum Genet* 2009; **17**: 228–235.
- 64 Biran J, Tahor M, Wircer E, Levkowitz G. Role of developmental factors in hypothalamic function. *Front Neuroanat* 2015; **9**: 47.
- 65 Jacobson L. Hypothalamic-pituitary-adrenocortical axis: neuropsychiatric aspects. *Compr Physiol* 2014; **4**: 715–738.
- 66 Guastella AJ, Hickie IB. Oxytocin treatment, circuitry and autism: a critical review of the literature placing oxytocin into the autism context. *Biol Psychiatry* 2015; **79**: 234–242.
- 67 Sestan-Pesa M, Horvath TL. Metabolism and mental illness. *Trends Mol Med* 2016; **22**: 174–183.
- 68 Branco T, Tozer A, Magnus CJ, Sugino K, Tanaka S, Lee AK *et al*. Near-perfect synaptic integration by Nav1.7 in hypothalamic neurons regulates body weight. *Cell* 2016; **165**: 1749–1761.
- 69 Green JJ, Hollander E. Autism and oxytocin: new developments in translational approaches to therapeutics. *Neurotherapeutics* 2010; **7**: 250–257.
- 70 Mari-Bauset S, Zazpe I, Mari-Sanchis A, Llopis-Gonzalez A, Morales-Suarez-Varela M. Food selectivity in autism spectrum disorders: a systematic review. *J Child Neurol* 2014; **29**: 1554–1561.
- 71 Staud R, Price DD, Janicke D, Andrade E, Hadjipanayis AG, Eaton WT *et al*. Two novel mutations of SCN9A (Nav1.7) are associated with partial congenital insensitivity to pain. *Eur J Pain* 2011; **15**: 223–230.
- 72 Mohler PJ, Rivolta I, Napolitano C, LeMaillet G, Lambert S, Priori SG *et al*. Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. *Proc Natl Acad Sci USA* 2004; **101**: 17533–17538.
- 73 Hsueh CH, Chen WP, Lin JL, Tsai CT, Liu YB, Juang JM *et al*. Distinct functional defect of three novel Brugada syndrome related cardiac sodium channel mutations. *J Biomed Sci* 2009; **16**: 23.
- 74 Ackerman MJ, Siu BL, Sturner WQ, Tester DJ, Valdivia CR, Makielski JC *et al*. Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. *JAMA* 2001; **286**: 2264–2269.
- 75 Kuzmenkin A, Jurkat-Rott K, Lehmann-Horn F, Mitrovic N. Impaired slow inactivation due to a polymorphism and substitutions of Ser-906 in the II-III loop of the human Nav1.4 channel. *Pflugers Arch* 2003; **447**: 71–77.



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/4.0/>

© The Author(s) 2018

Supplementary Information accompanies the paper on the Molecular Psychiatry website (<http://www.nature.com/mp>)